Medical physics

Konica Minolta Healthcare Sponsors SPIE Best Student Paper Award

Retrieved on: 
Thursday, March 14, 2024
Medical physics, Clinical research, Physics, Konica Minolta, International Society, Optics, SPIE, Science, Grace, University, Education, Patient, Research, History, Facilitation, Doctor of Philosophy, Minolta, University of Wisconsin–Madison, Iodine, Biological engineering, Signal-to-noise ratio, Health, Medical imaging

WAYNE, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Konica Minolta Healthcare Americas congratulates the winner and runners-up of the Best Student Paper Award given by the International Society for Optics and Photonics (SPIE) at its 2024 Medical Imaging Symposium in San Diego.

Key Points: 
  • WAYNE, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Konica Minolta Healthcare Americas congratulates the winner and runners-up of the Best Student Paper Award given by the International Society for Optics and Photonics (SPIE) at its 2024 Medical Imaging Symposium in San Diego.
  • With a history of 150 years of innovation, Konica Minolta is committed to fostering the development of advanced technologies to visualize what is not visible.
  • As a multinational company invested in research to deliver innovations in imaging technologies, Konica Minolta sponsored the award as part of its continued commitment to education and support of young scientists in medical imaging.
  • “Konica Minolta is proud to be a sponsor of the SPIE Medical Imaging Symposium and excited to support research and innovation in basic science applied to medical imaging,” says John Sabol, Clinical Research Manager, Konica Minolta Healthcare.

ICPO ACADEMY FOR THERANOSTICS to Grant EACCME Credits after Accreditation by Union Européenne des Médecins Spécialistes (UEMS)

Retrieved on: 
Wednesday, March 20, 2024
Research, Other Health, Radiology, Philanthropy, Oncology, Continuing, Hospitals, Education, Foundation, Clinical Trials, Science, Biotechnology, Health, Pillar, Medical physics, Union, American Medical Association, ICPO, Radiochemistry, Patient, Accreditation, Nursing, News, Cancer, Quality of life, Continuing medical education, CME, Licensure, Curriculum, Safety, Multimedia, Physician

We are thrilled to announce the prestigious accreditation form the Union Européenne des Médecins Spécialistes (UEMS), an esteemed institution dedicated to enhancing medical education and professional standards across Europe.

Key Points: 
  • We are thrilled to announce the prestigious accreditation form the Union Européenne des Médecins Spécialistes (UEMS), an esteemed institution dedicated to enhancing medical education and professional standards across Europe.
  • Odile Jaume, CEO of the ICPO Foundation, commented on the news of UEMS: "The accreditation from UEMS is a significant milestone for the ICPO ACADEMY FOR THERANOSTICS.
  • The ICPO ACADEMY FOR THERANOSTICS offers a comprehensive online educational program, developed by the ICPO Foundation and powered by its global community of experts.
  • For one of these pillars, participants of the ICPO ACADEMY FOR THERANOSTICS receives 10 credits for their educational training.

Volpara Health breast density and mammography quality software highlighted in new peer-reviewed research

Retrieved on: 
Wednesday, December 20, 2023
ASX, Mammography, Breast cancer, Software, Physics, Research, Patient safety, Cancer, 3D, Volpara, Radiation, Joint, Medical physics, Patient, VBD, 2D, Analytics, Algorithm, RSNA, Medical imaging

LYNNWOOD, Wash., Dec. 20, 2023 /PRNewswire/ -- Volpara Health Technologies Ltd. (ASX: VHT), a global leader in software for the early detection and prevention of cancer, was featured in two peer reviewed studies published during this year's Radiological Society of North America (RSNA) annual meeting.

Key Points: 
  • The report, "Breast dosimetry for standard and contrast-enhanced mammography and breast tomosynthesis," advocates for international harmonization of mammography dose estimates, by implementation of the new and improved model and methodology.
  • Featured in European Radiology , a second peer-reviewed study investigates whether active use of Volpara Analytics ® software could help breast radiographers to improve their screening image quality.
  • By empowering clinicians with innovative tools, Volpara exemplifies its commitment to advancing mammography quality and the early detection of breast cancer," said Melissa Hill, Volpara Health Senior Imaging Scientist and Global Research Lead.
  • Volpara strives for continuous advancements in AI for breast care, which aligns with the company's mission to save more families from cancer.

University of Wisconsin–Madison and GE HealthCare Broaden Shared Commitment to Healthcare Innovation

Retrieved on: 
Friday, November 17, 2023
Biotechnology, Health, Biometrics, Other Health, Radiology, Pharmaceutical, Surgery, Medical Devices, General Health, Hospitals, Science, Clinical Trials, Nursing, Medical Supplies, Prostate, Research, Chair, Liver, Liver disease, Cardiovascular disease, Particle, Patient, Nuclear medicine, Algorithm, Neurology, Artificial intelligence, Innovation Hub, Physics, Molecular imaging, Standard of care, University, MD, University of Wisconsin–Madison, Diagnosis, Deep learning, Public health, MRI, AI, Particle therapy, Physician, Biomedical technology, Medical physics, GE HealthCare, Medical imaging

The collaboration is aimed at shaping the future of medical imaging, to improve the standard of care and patient outcomes.

Key Points: 
  • The collaboration is aimed at shaping the future of medical imaging, to improve the standard of care and patient outcomes.
  • The decades-long history between GE HealthCare and UW–Madison has an established track record of combining innovative resources to transform patient care.
  • GE HealthCare and UW-Madison have also partnered to create standardized CT protocols for GE HealthCare systems that have been distributed to more than 4,000 sites globally.
  • GE HealthCare and UW-Madison have built a vital collaborative research and technology relationship , generating substantial health innovations including more than 100 patents.

GT Medical Technologies, Inc. Presents Use of GammaTile Therapy is Increasing in Time Across Several Brain Tumor Types at the 28th Annual Scientific Meeting and Education Day at the Society of Neuro-Oncology (SNO)

Retrieved on: 
Friday, November 17, 2023
Quality, Education, Radiation, Treatment, Brain metastasis, Seed, Glioblastoma, Brain, Convention, Patient, Abstract, Caesium, Pakistan Society of Neuro-Oncology, FDA, Quality of life, Meningioma, BED, Neuro, Cancer, Metastasis, Radiosurgery, Doctor of Philosophy, Neoplasm, Use, Society, Poster, SNO, Medical physics, Medical imaging, Glioma

TEMPE, Ariz., Nov. 17, 2023 /PRNewswire/ -- GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients with brain tumors, today announced an increase of clinical cases in the United States using its GammaTile® Therapy in patients diagnosed with several brain tumor types. The data was presented at the Society for Neuro-Oncology (SNO) 28th Annual Meeting and Education Day taking place from November 15-19, 2023, at the Vancouver Convention Center in Vancouver, Canada.

Key Points: 
  • The data was presented at the Society for Neuro-Oncology (SNO) 28th Annual Meeting and Education Day taking place from November 15-19, 2023, at the Vancouver Convention Center in Vancouver, Canada.
  • GammaTile has been used in over 1,000 patients with both newly diagnosed malignant brain tumors and recurrent brain tumors since 2019 and has been used in different tumor types, including glioblastoma, brain metastasis and meningioma.
  • Currently, GammaTile is sponsoring 4 clinical trials including a multi-institute registry trial (NCT0442738) that includes quality of life as a study metric.
  • GammaTile Therapy is a Surgically Targeted Radiation Therapy (STaRT) that delivers immediate radiation and eradicates brain tumor cells before they can replicate post-surgery while helping to protect healthy brain tissue.

RaySearch and MedAustron expand their partnership

Retrieved on: 
Friday, September 29, 2023
Partnership, RaySearch Laboratories, Medical physics, Cancer, Research, Carbon, Noetics, Proton, Patient, EBG, Pleasure, Environment, Software, Pharmaceutical industry

RaySearch and MedAustron have been collaborating since 2012, when MedAustron was RaySearch's first customer for carbon ion therapy treatment planning in RayStation®*.

Key Points: 
  • RaySearch and MedAustron have been collaborating since 2012, when MedAustron was RaySearch's first customer for carbon ion therapy treatment planning in RayStation®*.
  • In June 2019, MedAustron decided to replace other existing systems to exclusively use RaySearch software.
  • Ludwig Gold, Managing Director, MedAustron: "We are pleased that we have signed a collaboration agreement with RaySearch as one of the leading institutions in advanced cancer treatment solutions.
  • Björn Hårdemark, deputy CEO, RaySearch: "The work with MedAustron continues to be a source of inspiration.

IPG Photonics Announces Addition to its Board of Directors

Retrieved on: 
Tuesday, August 1, 2023
Proton, IPG, Regents of the University of Colorado, University, Chairperson, Psychology, Medical physics, Varian Medical Systems, Radiation therapy, ICU Medical, Growth

MARLBOROUGH, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- IPG Photonics Corporation (Nasdaq: IPGP) today announced that its Board of Directors has elected Kolleen Kennedy as a new director of the company, increasing the size of the Board to 11 members.

Key Points: 
  • MARLBOROUGH, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- IPG Photonics Corporation (Nasdaq: IPGP) today announced that its Board of Directors has elected Kolleen Kennedy as a new director of the company, increasing the size of the Board to 11 members.
  • “I am pleased to welcome Ms. Kennedy to the Board,” said John Peeler, non-executive Chair of the Board.
  • “Ms.
  • Ms. Kennedy has served as a member of the board of ICU Medical, Inc., manufacturer of medical technologies, since 2021.

Medtech: BrainTale Gathers €4.5 Million to Accelerate the Development of Its Solution for Diagnosis, Monitoring and Prediction of Neurological Disorders

Retrieved on: 
Tuesday, June 20, 2023
Medical Devices, Health, Neurology, Health Technology, Pharmaceutical, Biotechnology, Drug development, Adrenoleukodystrophy, Professor, ALD, ESPCI, Hospital, Medical physics, Ageing, DSM-IV codes, Software, Multimedia, Brain, Engineer, Biomarker, Doctor of Philosophy, Harvard University, Intensivist, MRI, Alzheimer's disease, Parkinson's disease, Magnetic resonance imaging, Neuroscience, Patient, Myenteric plexus, Physician, Coma, Observation, White matter, Diagnosis, ALS, Pharmaceutical industry, Medical imaging, Software as a service, Neuroradiology, Atlantic Ocean

To explore this new continent of the brain, BrainTale is developing a measurement solution that improves diagnosis, monitoring and prediction with a non-invasive, pain-free, efficient and clinically validated approach.

Key Points: 
  • To explore this new continent of the brain, BrainTale is developing a measurement solution that improves diagnosis, monitoring and prediction with a non-invasive, pain-free, efficient and clinically validated approach.
  • "This fundraising is a decisive step for BrainTale, and enables us to look forward with ambition to our next development milestones.
  • BrainTale improves the practice of healthcare professionals and the quality of care by improving the prediction of neurological diseases such as Alzheimer's and Parkinson's diseases.
  • This round of financing will enable BrainTale to enter a new phase in its development," states Sébastien Couvet, head of the MACSF Group's e-health portfolio.

Dr. Ehsan Samei Ph.D. joins Imalogix as Chief Scientific Advisor

Retrieved on: 
Tuesday, May 9, 2023
Duke University, Intellectual property, Carl, Electrical engineering, Deep learning, Radiology, Medical physics, Reed, Research, Medicine, Biomedical engineering, Computer engineering, Physics, Electricity, Duke University Health System, Medical imaging, Doctor of Philosophy

BRYN MAWR, Pa., May 9, 2023 /PRNewswire/ -- Imalogix, an industry leader in deep learning AI for imaging, announced that world renowned radiology leader and clinical researcher Dr. Ehsan Samei has joined the Imalogix team as its Chief Scientific Advisor.

Key Points: 
  • BRYN MAWR, Pa., May 9, 2023 /PRNewswire/ -- Imalogix, an industry leader in deep learning AI for imaging, announced that world renowned radiology leader and clinical researcher Dr. Ehsan Samei has joined the Imalogix team as its Chief Scientific Advisor.
  • World renowned radiology leader and clinical researcher Dr. Ehsan Samei joins Imalogix team as Chief Scientific Advisor.
  • Dr. Ehsan Samei, PhD, DABR, FAAPM, FSPIE, FAIMBE, FIOMP, FACR is the Reed and Martha Rice Distinguished Professor of Radiology at Duke University, where he holds additional appointments in Medical Physics, Biomedical Engineering, Physics, and Electrical and Computer Engineering.
  • Author of over 350 referred papers, his work has aimed to bridge the gap between scientific scholarship and clinical practice through patient-centric imaging and translational research.

Varian Users Achieve Key Milestones in Adoption of HyperSight Imaging Solution

Retrieved on: 
Thursday, March 30, 2023
Canada, Investigational New Drug, CBCT, Nova Scotia Health Authority, Workflow, PALO, Operation of computed tomography, Medical physics, Head, Radiation therapy, Associate, Trial of the century, Huntsman Cancer Institute, Siemens Healthineers, Acquisition, MD, Patient, Physics, Neoplasm, Health Canada, Medical imaging, Varian, Ethos

Varian has completed the first commercial installation in the world of a new Halcyon system equipped with HyperSight at Huntsman Cancer Institute.

Key Points: 
  • Varian has completed the first commercial installation in the world of a new Halcyon system equipped with HyperSight at Huntsman Cancer Institute.
  • Health Canada has granted Investigational Testing Authorization for a clinical study evaluating the potential benefits of Varian's HyperSight imaging solution.
  • We look forward to continuing to collaborate with Varian to drive further adoption and innovation of this promising technology."
  • Varian recently completed the first commercial installation of a new Halcyon system equipped with HyperSight at Huntsman Cancer Institute in Salt Lake City, Utah.